MiMedx Group Inc
NASDAQ:MDXG
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.51
9.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
MiMedx Group Inc
MiMedx Group Inc
Cash & Cash Equivalents
MiMedx Group Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MiMedx Group Inc
NASDAQ:MDXG
|
Cash & Cash Equivalents
$88.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$7.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$6.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
MiMedx Group Inc
Glance View
MiMedx Group Inc. is a fascinating player in the realm of life sciences, operating at the dynamic intersection of biotechnology and tissue engineering. Nestled in the healthcare sector, MiMedx specializes in developing and distributing regenerative biomaterials and allografts derived from human amniotic tissue. This niche focus allows the company to tap into the potential of natural biologics to promote effective healing and enhance patient outcomes, particularly in chronic and complex wound care. Their product offerings, which primarily include amniotic membrane and umbilical cord products, are harnessed to aid in tissue repair and to reduce inflammation and scarring, all of which are critical elements in successful clinical treatment. In terms of revenue generation, MiMedx's business model revolves around an intricate balance of innovation and strategic partnerships. By meticulously refining their proprietary processing techniques, the company maintains a competitive advantage that appeals to healthcare providers across various specialties, including orthopedics, podiatry, and reconstructive surgery. Revenue streams are predominantly driven by the sale of these biotechnology innovations to hospitals, healthcare providers, and through direct distribution channels. Further enhancing their financial robustness, MiMedx invests in extensive clinical trials and research, which underpin their marketing and educational efforts to broaden the adoption of their products. With a keen eye on developing medical solutions that cater to an aging population and a growing demand for effective wound care products, MiMedx positions itself as a crucial innovator in its sector.
See Also
What is MiMedx Group Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
88.8m
USD
Based on the financial report for Sep 30, 2024, MiMedx Group Inc's Cash & Cash Equivalents amounts to 88.8m USD.
What is MiMedx Group Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
7%
Over the last year, the Cash & Cash Equivalents growth was 9%. The average annual Cash & Cash Equivalents growth rates for MiMedx Group Inc have been -1% over the past three years , -1% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
